Lamotrigine clearance during pregnancy

T. A. Tran, Ilo E Leppik, K. Blesi, S. T. Sathanandan, Rory P Remmel

Research output: Contribution to journalArticle

191 Citations (Scopus)

Abstract

Objective: To evaluate changes in lamotrigine (LTG) clearance before, during, and after pregnancy. Methods: Twelve pregnancies that had complete steady-state data before, during, and after pregnancy were evaluated. Data included weight, LTG dose, and LTG blood levels at preconception, during pregnancy, and postpartum, and concomitant use of other antiepileptic drugs and their dosages. Apparent clearance (L/[kg·day]) of LTG was calculated by dose/level/ weight for time points at preconception; during the first trimester, second trimester, and third trimester; and postpartum. Apparent clearance was compared between preconception and each of the three trimesters. Statistical analysis was performed using one-way analysis of variance, the Student-Newman-Keuls test, and the paired Student's t-test. Results: An increase in apparent clearance (>65%) was observed between preconception and the second and third trimesters (p < 0.05). Eleven pregnancies required higher doses of LTG to maintain therapeutic levels during pregnancy. There was no significant change in apparent clearance between each trimester. A decrease in apparent clearance was observed between the last two trimesters and postpartum (p < 0.05). In the postpartum period, apparent clearances returned to the preconception baseline, and LTG doses needed to be reduced. Conclusion: Pregnancy increases LTG clearance by <50% This effect occurs early in pregnancy and reverts quickly after delivery. LTG levels should be monitored before, during, and after pregnancy.

Original languageEnglish (US)
Pages (from-to)251-255
Number of pages5
JournalNeurology
Volume59
Issue number2
DOIs
StatePublished - Jul 23 2002

Fingerprint

Pregnancy
Postpartum Period
Third Pregnancy Trimester
Second Pregnancy Trimester
Students
lamotrigine
Weights and Measures
First Pregnancy Trimester
Anticonvulsants
Analysis of Variance

Cite this

Lamotrigine clearance during pregnancy. / Tran, T. A.; Leppik, Ilo E; Blesi, K.; Sathanandan, S. T.; Remmel, Rory P.

In: Neurology, Vol. 59, No. 2, 23.07.2002, p. 251-255.

Research output: Contribution to journalArticle

Tran, TA, Leppik, IE, Blesi, K, Sathanandan, ST & Remmel, RP 2002, 'Lamotrigine clearance during pregnancy', Neurology, vol. 59, no. 2, pp. 251-255. https://doi.org/10.1212/WNL.59.2.251
Tran, T. A. ; Leppik, Ilo E ; Blesi, K. ; Sathanandan, S. T. ; Remmel, Rory P. / Lamotrigine clearance during pregnancy. In: Neurology. 2002 ; Vol. 59, No. 2. pp. 251-255.
@article{c1de78c9048240bebc973b1aa60661eb,
title = "Lamotrigine clearance during pregnancy",
abstract = "Objective: To evaluate changes in lamotrigine (LTG) clearance before, during, and after pregnancy. Methods: Twelve pregnancies that had complete steady-state data before, during, and after pregnancy were evaluated. Data included weight, LTG dose, and LTG blood levels at preconception, during pregnancy, and postpartum, and concomitant use of other antiepileptic drugs and their dosages. Apparent clearance (L/[kg·day]) of LTG was calculated by dose/level/ weight for time points at preconception; during the first trimester, second trimester, and third trimester; and postpartum. Apparent clearance was compared between preconception and each of the three trimesters. Statistical analysis was performed using one-way analysis of variance, the Student-Newman-Keuls test, and the paired Student's t-test. Results: An increase in apparent clearance (>65{\%}) was observed between preconception and the second and third trimesters (p < 0.05). Eleven pregnancies required higher doses of LTG to maintain therapeutic levels during pregnancy. There was no significant change in apparent clearance between each trimester. A decrease in apparent clearance was observed between the last two trimesters and postpartum (p < 0.05). In the postpartum period, apparent clearances returned to the preconception baseline, and LTG doses needed to be reduced. Conclusion: Pregnancy increases LTG clearance by <50{\%} This effect occurs early in pregnancy and reverts quickly after delivery. LTG levels should be monitored before, during, and after pregnancy.",
author = "Tran, {T. A.} and Leppik, {Ilo E} and K. Blesi and Sathanandan, {S. T.} and Remmel, {Rory P}",
year = "2002",
month = "7",
day = "23",
doi = "10.1212/WNL.59.2.251",
language = "English (US)",
volume = "59",
pages = "251--255",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Lamotrigine clearance during pregnancy

AU - Tran, T. A.

AU - Leppik, Ilo E

AU - Blesi, K.

AU - Sathanandan, S. T.

AU - Remmel, Rory P

PY - 2002/7/23

Y1 - 2002/7/23

N2 - Objective: To evaluate changes in lamotrigine (LTG) clearance before, during, and after pregnancy. Methods: Twelve pregnancies that had complete steady-state data before, during, and after pregnancy were evaluated. Data included weight, LTG dose, and LTG blood levels at preconception, during pregnancy, and postpartum, and concomitant use of other antiepileptic drugs and their dosages. Apparent clearance (L/[kg·day]) of LTG was calculated by dose/level/ weight for time points at preconception; during the first trimester, second trimester, and third trimester; and postpartum. Apparent clearance was compared between preconception and each of the three trimesters. Statistical analysis was performed using one-way analysis of variance, the Student-Newman-Keuls test, and the paired Student's t-test. Results: An increase in apparent clearance (>65%) was observed between preconception and the second and third trimesters (p < 0.05). Eleven pregnancies required higher doses of LTG to maintain therapeutic levels during pregnancy. There was no significant change in apparent clearance between each trimester. A decrease in apparent clearance was observed between the last two trimesters and postpartum (p < 0.05). In the postpartum period, apparent clearances returned to the preconception baseline, and LTG doses needed to be reduced. Conclusion: Pregnancy increases LTG clearance by <50% This effect occurs early in pregnancy and reverts quickly after delivery. LTG levels should be monitored before, during, and after pregnancy.

AB - Objective: To evaluate changes in lamotrigine (LTG) clearance before, during, and after pregnancy. Methods: Twelve pregnancies that had complete steady-state data before, during, and after pregnancy were evaluated. Data included weight, LTG dose, and LTG blood levels at preconception, during pregnancy, and postpartum, and concomitant use of other antiepileptic drugs and their dosages. Apparent clearance (L/[kg·day]) of LTG was calculated by dose/level/ weight for time points at preconception; during the first trimester, second trimester, and third trimester; and postpartum. Apparent clearance was compared between preconception and each of the three trimesters. Statistical analysis was performed using one-way analysis of variance, the Student-Newman-Keuls test, and the paired Student's t-test. Results: An increase in apparent clearance (>65%) was observed between preconception and the second and third trimesters (p < 0.05). Eleven pregnancies required higher doses of LTG to maintain therapeutic levels during pregnancy. There was no significant change in apparent clearance between each trimester. A decrease in apparent clearance was observed between the last two trimesters and postpartum (p < 0.05). In the postpartum period, apparent clearances returned to the preconception baseline, and LTG doses needed to be reduced. Conclusion: Pregnancy increases LTG clearance by <50% This effect occurs early in pregnancy and reverts quickly after delivery. LTG levels should be monitored before, during, and after pregnancy.

UR - http://www.scopus.com/inward/record.url?scp=0037162365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037162365&partnerID=8YFLogxK

U2 - 10.1212/WNL.59.2.251

DO - 10.1212/WNL.59.2.251

M3 - Article

C2 - 12136066

AN - SCOPUS:0037162365

VL - 59

SP - 251

EP - 255

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 2

ER -